Reimbursement begins slowly for Biogen’s expensive Alzheimer’s drug

Medicare Administrative Contractors, or MACs, are now sporadically reimbursing for Biogen’s expensive new Alzheimer’s drug in limited pockets across the US, as CMS has several months left to finish its decision on national coverage.